PPIDT00318
Drug Information
| Name | Vosoritide |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB11928 |
| Type | biotech |
| Indication | Vosoritide is indicated for the promotion of linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses.[L39229] This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).[L48571] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | Subcutaneous |
0.4 mg
|
| Injection, powder, for solution | Subcutaneous |
0.56 mg
|
| Injection, powder, for solution | Subcutaneous |
1.2 mg
|
| Injection, powder, lyophilized, for solution; kit | Subcutaneous |
0.4 mg/0.5mL
|
| Injection, powder, lyophilized, for solution; kit | Subcutaneous |
0.56 mg/0.7mL
|
| Injection, powder, lyophilized, for solution; kit | Subcutaneous |
1.2 mg/0.6mL
|